Purpose: prospective, randomized clinical trial on advanced Hodgkin's lymphoma (HL), In this multicenter doxorubicin, vinblastine, mechloreththe efficacy and toxicity of two chemotherapy regimens, annine, vincristine, bleomycin, etoposide, and prednisone (Stanford V) and mechlorethamine, vincristine, procarbazine, prednisone, epidoxirubicin, bleomycin, vinblastine, lomustine, doxorubicin, and vindesine (MOPPEBVCAD), were compared with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as standard therapy to select which regimen would best support a reduced radiotherapy program, which was limited to <= two sites of either previous bulky or partially remitting disease (a modification of the original Stanford program). Patients and Methods: Three hundred fifty-five patients with stage IIB, III, or IV HL were randomly assigned. Three hundred thirty-four patients were assessable for the study and received six cycles of ABVD (n = 122), three cycles of Stanford V (n = 107), or six cycles of MOPPEBVCAD (n = 106); radiotherapy was administered to 76, 71, and 50 patients in these three arms, respectively. Results: The complete response rates for ABVD, Stanford V, and MOPPEBVCAD were 89%, 76% and 94%, respectively; 5-year failure-free survival (FFS) and progression-free survival rates were respectively (P < .01 for comparison of Stanford V with the other two regimens). Corresponding 5-year overall survival rates were 90%, 82%, and 89% for ABVD, Stanford V, and MOPPEBVCAD, respectively. Stanford V was more myelotoxic than ABVD but less myelotoxic than MOPPEBVCAD, which had larger reductions in the prescribed drug doses. Conclusion: When associated with conditioned and limited (not adjuvant) radiotherapy, ABVD and MOPPEBVCAD were superior to Stanford V chemotherapy in terms of response rate and FFS and progression-free survival. Patients were irradiated less often after MOPPEBVCAD, but this regimen was more toxic. ABVD is still the best choice when it is combined with limited irradiation.
|Data di pubblicazione:||2005|
|Titolo:||ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi|
|Autore/i:||Gobbi, Pg; Levis, A; Chisesi, T; Broglia, C; Vitolo, U; Stelitano, C; Pavone, V; Cavanna, L; Santini, G; Merli, F; Liberati, M; Baldini, L; Deliliers, Gl; Angelucci, E; Bordonaro, R; Federico, Massimo|
|Digital Object Identifier (DOI):||10.1200/JCO.2005.02.907|
|Codice identificativo ISI:||WOS:000234230400025|
|Codice identificativo Scopus:||2-s2.0-31144465569|
|Codice identificativo Pubmed:||16172458|
|Citazione:||ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi / Gobbi, Pg; Levis, A; Chisesi, T; Broglia, C; Vitolo, U; Stelitano, C; Pavone, V; Cavanna, L; Santini, G; Merli, F; Liberati, M; Baldini, L; Deliliers, Gl; Angelucci, E; Bordonaro, R; Federico, Massimo. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 23 (36)(2005), pp. 9198-9207.|
|Tipologia||Articolo su rivista|
I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris